sorafenib has been researched along with hydrazine in 3 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (hydrazine) | Trials (hydrazine) | Recent Studies (post-2010) (hydrazine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 12,034 | 330 | 3,193 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, X; Feng, Z; Li, C; Li, Y; Niu, F; Tang, K; Yang, H; Zhang, L; Zhou, W | 1 |
| Fukunaga, K; Iwasaki, K; Kohno, K; Kurokawa, T; Murata, S; Ohkohchi, N; Zheng, YW | 1 |
| Franken, MG; Gheorghe, M; Haanen, JBAG; Leeneman, B; Uyl-de Groot, CA; van Baal, PHM | 1 |
1 review(s) available for sorafenib and hydrazine
| Article | Year |
|---|---|
A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Benzimidazoles; Cancer Vaccines; Carboplatin; Dacarbazine; gp100 Melanoma Antigen; Humans; Hydrazines; Imidazoles; Interleukin-2; Ipilimumab; Lenalidomide; Melanoma; Network Meta-Analysis; Nitrosourea Compounds; Nivolumab; Organophosphorus Compounds; Oximes; Paclitaxel; Piperidines; Progression-Free Survival; Proportional Hazards Models; Pyridones; Pyrimidinones; Skin Neoplasms; Sorafenib; Survival Rate; Temozolomide; Treatment Outcome; Vemurafenib | 2019 |
2 other study(ies) available for sorafenib and hydrazine
| Article | Year |
|---|---|
The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.
Topics: Animals; beta Catenin; Blotting, Western; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Hydrazines; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2015 |
The Eltrombopag antitumor effect on hepatocellular carcinoma.
Topics: Apoptosis; Benzoates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrazines; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Receptors, Thrombopoietin; Sorafenib | 2015 |